Orchard Therapeutics — Conference Presentation (January 2020)
27 slides from Orchard Therapeutics's conference presentation, Jan 13, 2020
Slide 1: Dedicated to Transforming the Lives of Patients Through Innovative Gene Therapies
Dedicated to Transforming the Lives of Patients Through Innovative Gene Therapies January 13 - 15, 2020 Exhibit 99.2
Slide 2: Forward Looking Statements
Forward Looking Statements | Certain information set forth in this presentation and in statements made orally during this presentation contains “forward-looking statements”. Except for statements of historical fact, information contained herein constitutes forward-looking statements and includes, bu
Slide 3: Global gene therapy company dedicated to patients with rare diseases
Global gene therapy company Dedicated to transforming the lives of patients with rare diseases Focused today on ex-vivo autologous HSC gene therapy | Confidential Orchard Therapeutics
Slide 4: The Orchard Therapeutics Story: Strong Fundamentals
| THE ORCHARD THERAPEUTICS STORY Strong Momentum – Transformative Year Ahead 1 Strong Fundamentals 2 Powerful Platform Approach 3 Commercial Ready 4 Our Future
Slide 5: Compelling Fundamentals Driving Near and Long-term Growth
Compelling Fundamentals Driving Near and Long-term Growth | Highly leverageable platform approach to gene therapy; potential to address numerous rare diseases Strong balance sheet (~$325M as of YE 2019) to fund the business into the second half of 2021 1Based on target label and pricing of recent ge
Slide 6: One of the Deepest Pipelines in Gene Therapy
One of the Deepest Pipelines in Gene Therapy MAA decision BLA late 2020 / early 2021 Initiate rolling BLA 1H 2020 MAA & BLA submissions 2021 Interim POC data - 2020 Interim POC data - 2020 |
Slide 7: Building a Scalable Business in Rare Diseases
Building a Scalable Business in Rare Diseases | 1Based on target label and pricing of recent gene therapy analogs Incidence / prevalence figure estimates based on available literature, population data and in-house estimates, in countries where rare disease therapies are typically reimbursed. Higher
Slide 8: Annual Incidence
Annual Incidence 80% 80% 80% | 1Based on target label and pricing of recent gene therapy analogs Incidence / prevalence figure estimates based on available literature, population data and in-house estimates, in countries where rare disease therapies are typically reimbursed. Higher incidence rates h
Slide 9: The Orchard Therapeutics Story: Powerful Platform Approach
| THE ORCHARD THERAPEUTICS STORY Strong Momentum – Transformative Year Ahead 1 Strong Fundamentals 2 Powerful Platform Approach 3 Commercial Ready 4 Our Future
Slide 10: HSC Gene Therapy Offers a Highly Differentiated Approach
HSC Gene Therapy Offers a Highly Differentiated Approach | Integration Self-renewal One-time administration Monocyte / Macrophage / Microglia T cells B cells NK cells Megakaryocyte Erythrocyte Granulocyte Potential for permanent disease correction Differentiates into multiple cell types
Slide 11: Potential to Correct Multiple Cell Types Addresses Many Rare Diseases
Potential to Correct Multiple Cell Types Addresses Many Rare Diseases | Immune System MLD MPS-I MPS-IIIA MPS-IIIB ADA-SCID WAS X-CGD WAS TDT Monocyte / Macrophage / Microglia T cells B cells NK cells Megakaryocyte Erythrocyte Granulocyte Central Nervous System Immune System Blood Cell and Platelet L
Slide 12: Durability of Response Out to 18+ Years
Durability of Response Out to 18+ Years with > 170 Patients Treated | Patients treated in the development phase, including in clinical trials and under pre-approval access (defined as any form of pre-approval treatment outside of a company-sponsored clinical trial, including, but not limited to, com
Slide 13: The Orchard Therapeutics Story: Commercial Ready
| THE ORCHARD THERAPEUTICS STORY Strong Momentum – Transformative Year Ahead 1 Strong Fundamentals 2 Powerful Platform Approach 3 Commercial Ready 4 Our Future
Slide 14: Metachromatic Leukodystrophy is a Devastating, Rapidly Progressive Disease
Metachromatic Leukodystrophy is a Devastating, Rapidly Progressive Disease | Disease Snapshot Fatal genetic CNS disorder Relentless loss of physical and cognitive function Presents on a spectrum with different ages of onset Age 5, pre-diagnosis Age 9, advanced disease
Slide 15: Significantly Superior Motor and Cognitive Function vs. Natural History
Significantly Superior Motor and Cognitive Function Demonstrated vs. Natural History | Both LI and EJ patients achieved a statistically significant difference on the co-primary endpoint of improvement of >10% of the total GMFM score in treated subjects when compared to the Natural History cohort at
Slide 16: Implementing Commercial Strategy to Launch OTL-200 Globally
Implementing Commercial Strategy to Launch OTL-200 Globally | Market Access 4 Multi-stakeholder engagement Gene therapy value determination Option for flexible payment models Patient ID and Diagnostics 1 Disease awareness and diagnostic testing Extensive newborn screening pilot testing efforts in EU
Slide 17: Multi-Pronged Approach to Identifying MLD Patients
Multi-Pronged Approach to Identifying MLD Patients Confidential | Disease and Diagnostic Education Diagnostic Initiatives Newborn Screening Patient Identification Identify first symptoms and drive early suspicion KOL engagement and education of general pediatricians Peer to peer education Assay deve
Slide 18: Establish Commercial and Operational Model: Phase 1
Establish Commercial and Operational Model: Building Teams and Infrastructure to Serve Patients Worldwide | Middle East includes GCC countries and Israel Phase 1 - 2019 / 2020 EU, Middle East 25 commercial FTEs 4 - 6 treatment centers planned Newborn screening pilots initiating (EU & U.S.) Penetrati
Slide 19: Establish Commercial and Operational Model: Phase 2
Establish Commercial and Operational Model: Building Teams and Infrastructure to Serve Patients Worldwide | Middle East includes GCC countries and Israel Phase 2 - 2020 / 2021 U.S. Penetration and reimbursement varies by market
Slide 20: Establish Commercial and Operational Model: Phase 3
Establish Commercial and Operational Model: Building Teams and Infrastructure to Serve Patients Worldwide | Middle East includes GCC countries and Israel Phase 3 - 2021 / 2022 LatAm, ROW Penetration and reimbursement varies by market
Slide 21: Manufacturing in Place to Support Commercialization
Manufacturing in Place to Support Commercialization | MolMed producing drug product and vector Sufficient inventory being produced to meet expected launch demand Leveraging commercial process experience from Strimvelis CMO Infrastructure Established for Initial MLD Launch NEAR TERM Continue partners
Slide 22: Drive Global Access: Our Pricing Commitments
Drive Global Access: Our Pricing Commitments | Shared value Ensure patients, society and industry share in human and economic benefits of innovation – now and in the future Shared risk Stand behind therapeutic outcomes and be willing to tie payment to outcomes Informed pricing Use demonstrable, obje
Slide 23: The Orchard Therapeutics Story: Our Future
| THE ORCHARD THERAPEUTICS STORY Strong Momentum – Transformative Year Ahead 1 Strong Fundamentals 2 Powerful Platform Approach 3 Commercial Ready 4 Our Future
Slide 24: Investment to Scale and Innovate Across Our Business
Investment to Scale and Innovate Across Our Business | PRODUCT PROCESS Transduction enhancers Non-toxic conditioning HSC subsets Stable cell line Closed automated systems Manufacturing facility (expected operational in 2021) Research and discovery for new indications in 2020 Technology innovations I
Slide 25: Gene-corrected HSCs and Macrophage Progeny Can Address Brain and Other Organ Disorders
Gene-corrected HSCs and Macrophage Progeny Can Address Brain and Other Organ System Disorders | Other rare indications Potential non-rare (longer-term) Other Organ Systems Brain Macrophage High area of focus Potential future exploration Literature references: Alessia Capotondo, Rita Milazzo, Letteri
Slide 26: Building on our Strength in Neurometabolic Disorders
Building on our Strength in Neurometabolic Disorders | MPS-IIIB Preclinical MPS-I MPS-IIIA Interim POC data in 2020 MLD Pre-commercial / filed with EMA Multiple new neurodegenerative disorders Potential applications in larger / non-rare conditions Brain Research Undisclosed External collaboration Dr
Slide 27: Corporate Priorities & Expected Key Milestones
Corporate Priorities & Expected Key Milestones | ADA-SCID Initiate a rolling BLA in the U.S. for OTL-101 in 1H 2020 with completion within 12 months MLD Submit a BLA filing in late 2020 or early 2021 Obtain approval and launch OTL-200 for MLD in Europe in 2H 2020 MPS-I Release interim data from POC
Orchard Therapeutics — Conference Presentation (January 2020) on 6ix